Dexcel Pharma
Dexcel Pharma is a privately held Israeli pharmaceutical company that develops, manufactures, and commercializes branded prescription drugs, generic medicines, and OTC products across multiple dosage forms. It serves healthcare providers, pharmacies, distributors, and consumers through subsidiaries in the US, Israel, UK, Germany, and Austria.
- Company typePrivate
- Founded-
- HeadquartersOr Akiva, Israel
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dexcel Pharma does
Dexcel Pharma is a privately owned pharmaceutical company headquartered in Or Akiva, Israel, with 1,001–5,000 employees. It develops, manufactures, and commercializes a diversified portfolio of branded prescription drugs, over-the-counter products (including national brands and private-label lines), and generic medicines—including established, niche, and first-to-market generics in various dosage forms. The company states R&D capabilities across multiple drug modalities: small molecules, biologics, oligonucleotides, and genetic medicine.
Dexcel commercializes its products globally through wholly-owned regional subsidiaries in five key markets—the United States (Dexcel USA), Israel (Dexcel Israel), the United Kingdom (Dexcel UK), Germany (Dexcel Germany), and Austria (Dexcel Austria)—supplemented by a network of third-party distributors and partners for broader geographic reach. Its customer base spans three primary segments: healthcare providers (physicians, hospitals, healthcare systems) for branded Rx, retail pharmacies and pharmaceutical distributors for OTC and generics, and end consumers purchasing OTC products through retail channels.
The revenue model is product-sale driven across all three product categories, with pricing not publicly disclosed. The company describes itself as investing in R&D and commercialization of novel drugs and technologies, and operates as an independent private entity with no disclosed parent company, institutional investors, M&A history, management roster, or financial metrics in the available source material.
Dexcel Pharma firmographics
Firmographics- Name
- Dexcel Pharma
- Legal name
- Dexcel Pharma
- Website
- https://dexcelpharma.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Dexcel Pharma is a privately held Israeli pharmaceutical company that develops, manufactures, and commercializes branded prescription drugs, generic medicines, and OTC products across multiple dosage forms. It serves healthcare providers, pharmacies, distributors, and consumers through subsidiaries in the US, Israel, UK, Germany, and Austria.
- Ownership category
- akta.pro rank
Dexcel Pharma industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Oral Solid Dose (OSD) Generics (HLAIABAD), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Dexcel Pharma is headquartered
LocationHeadquarters
- HQ city
- Or Akiva
- HQ country
- Israel
- HQ region
- Middle East
Offices5 records
Markets served
Dexcel Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Branded Rx Products: Sale of innovative branded prescription pharmaceutical drugs across therapeutic areas
- OTC Products: Sale of over-the-counter pharmaceuticals including national brands and private-label products
- Generic Drugs: Sale of generic pharmaceutical products including established, niche, and first-to-market drugs in various dosage forms
Distribution channels3 records
Dexcel Pharma product offering
Product offeringCore offering
Dexcel Pharma develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (national brands and private-label over-the-counter pharmaceuticals), and Generics (established, niche, and first-to-market generic drugs in various dosage forms). The company operates R&D and manufacturing capabilities across small molecules, biologics, oligonucleotides, and genetic medicine, and commercializes products globally through its own affiliates, distributors, and partners.
Product overview
Dexcel Pharma offers a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (over-the-counter national brands and private-label pharmaceuticals), and Generics (broad portfolio of established, niche, and first-to-market generic drugs in various dosage forms). The company is involved in development, manufacturing, and commercialization of these products globally.
Differentiator
Problem solved
Functional benefit
Brands
- Branded Rx: Innovative drugs across therapeutic areas
- OTC
- Generics
Products and services
- Branded Rx
Companies that use Dexcel Pharma
Customer profileSegments3 records
Ideal customer profiles3 records
Dexcel Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Dexcel Pharma partnerships and signals
Strategic signalScale indicators2 records
Recent moves3 records
Expansion highlights4 records
Dexcel Pharma competitors and assessment
Company assessmentDirect peers
- Aurobindo Pharma: India-headquartered generics and specialty manufacturer with broad US and European presence. Comparable diversified portfolio with strong generics focus.
- Apotex: Privately held Canadian pharma focused on generics, biosimilars, and innovative medicines. Comparable private ownership structure and generics-heavy portfolio.
- Teva Pharmaceutical Industries: Israeli-headquartered global pharma with a broad generics, specialty, and OTC portfolio. Most direct geographic and portfolio comparable to Dexcel, though significantly larger in scale.
- Sandoz (Novartis): Global generics and biosimilars manufacturer spun out of Novartis. Closely comparable business model to Dexcel's generics and specialty segments with broader geographic reach.
- Viatris: Global pharma formed via Mylan-Upjohn merger, focused on generics, branded, and biosimilars. Comparable diversified product mix and global commercial footprint.
- Perrigo Company: Consumer-focused pharma emphasizing OTC and store-brand generics. Highly comparable to Dexcel's OTC and private-label franchise and similar in size/scale.
- Hikma Pharmaceuticals: MENA-headquartered pharma with branded, generic, and injectable businesses across the US, Europe, and MENA. Comparable mid-sized international footprint and product mix.
- Dr. Reddy's Laboratories: India-based global pharma with generics, APIs, and branded formulations across regulated and emerging markets. Comparable generic-plus-branded portfolio with international affiliates.
- Lupin Pharmaceuticals: India-based pharma with generics, specialty, and biosimilars across US, Europe, and emerging markets. Similar diversified business model and therapeutic breadth.
- Endo International: Specialty and generics pharma with focus on sterile injectables and established brands. Comparable mid-sized diversified pharma operating model in US and select international markets.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Dexcel Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dexcel Pharma leadership team
Management profileNumber of profiles
Dexcel Pharma subsidiaries and ownership
Company hierarchySubsidiaries5 records
Dexcel Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dexcel Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dexcel Pharma
What does Dexcel Pharma do?
Dexcel Pharma develops, manufactures, and commercializes a diversified portfolio of pharmaceutical products organized into three core categories: Branded Rx (innovative prescription drugs across therapeutic areas), OTC (national brands and private-label over-the-counter pharmaceuticals), and Generics (established, niche, and first-to-market generic drugs in various dosage forms). The company operates R&D and manufacturing capabilities across small molecules, biologics, oligonucleotides, and genetic medicine, and commercializes products globally through its own affiliates, distributors, and partners.
Is Dexcel Pharma a public or private company?
Dexcel Pharma is a private company. It is classified as unknown and is currently operating.
When was Dexcel Pharma founded?
Dexcel Pharma was founded in -1. It employs 1,001 to 5,000 people.
Where is Dexcel Pharma based?
Dexcel Pharma is headquartered in Or Akiva, Israel, in the Middle East region.
How does Dexcel Pharma make money?
Three revenue lines are on record. Branded Rx Products are the primary driver. The others are OTC Products and generic Drugs.
Who are Dexcel Pharma's main competitors?
Direct peers on record are Aurobindo Pharma, Apotex, Teva Pharmaceutical Industries, Sandoz (Novartis), Viatris, Perrigo Company, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Lupin Pharmaceuticals and Endo International.
Does Dexcel Pharma have an API?
No public API is recorded for Dexcel Pharma.
What industry is Dexcel Pharma in?
Dexcel Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIABAD, Oral Solid Dose (OSD) Generics. Its NAICS code is 325412 and its SIC code is 2834.